There is no consensus regarding a best dosing regimen of hepatitis B virus vaccine (HBVV) for non-responsive HIV-infected individuals. Double-dose of hepatitis B vaccine (DDHBVV) could enhance immunogenicity to HBVV in non-responsive HIVinfected adults. We assessed the immunogenicity of DDHBVV in HIV-infected adolescents who failed to respond to standard HBVV revaccination. HIV-infected adolescents with current CD4 200 cells/mm 3 and no protective antibody concentration of hepatitis B surface antibodies (antiHBs) after HBVV revaccination received DDHBVV, at months 0, 1, 2. The HBVV doses were 20 microgram per dose for adolescents aged < 18 years and 40 microgram per dose for adolescents aged 18 years. AntiHBs titers were measured at 1, 2, 3 months after first DDHBVV. AntiHBs 10 mIU/ml was considered protective. Seven adolescents were enrolled; mean age was 15.4 years, CD4 was 775 cells/mm 3 and all had HIV-RNA < 50 copies/ml. Proportions of adolescents with protective antiHBs were 86% at months 1 and 2, and 100% at month 3. Geometric means of antiHBs were 1.1 at baseline, 101.6 at 1 month, 137.1 at 2 months, and 355.9 mIU/ml at 3 months after the first DDHBVV. No grade 3-4 adverse event was reported. DDHBVV is an option for HIV-infected adolescents who are non-responder to standard HBVV revaccination.
According to the US Centers for Disease Control recommendation, individuals who failed to develop a protective serum antibody concentration of hepatitis B surface antibody (antiHBs) >10 mIU/mL after a first course of 3 doses of hepatitis B virus vaccine (HBVV) should at least be given a second 3-dose course of HBVV. 1 However, there is no consensus regarding a best dosing regimen of HBVV for nonresponsive HIVinfected individuals. Double dose of hepatitis B vaccine (DDHBVV) could enhance the immunogenicity to HBVV in nonresponders. Response rates of 51% to 85% to 3 doses of DDHBVV have been reported in previous nonresponder, HIV-infected adults, and response rate was superior to revaccination with standard doses of HBVV. [2] [3] [4] There are limited data on DDHBVV in HIV-infected children and adolescents. Here, we report a pilot, open-label, single-arm study to evaluate the efficacy and safety of DDHBVV in HIV-infected adolescents who were nonresponders even though they previously received the first HBVV course during infancy and second HBVV course after immune recovery.
Recombinant HBVV, manufactured by LG Life Science, Korea (Euvax B, Lot no. ULA08005 and ULA09007) and distributed by Sanofi Pasteur Ltd, Korea, was used. Each 1 mL of vaccine contained 20 mg of hepatitis B surface antigen (HBsAg) with aluminium hydroxide gel. The standard pediatric dose (recommended for individuals <15 years of age) contains 10 mg of HBsAg in a volume of 0.5 mL, while the adult dose (recommended for individuals 16 years of age) contains 20 mg of HBsAg in a volume of 1.0 mL. In our study, the HBVV doses were 20 mg per dose for adolescents aged <18 years and 40 mg per dose for adolescents aged 18 years. 3 The vaccines were administered intramuscularly at months 0, 1, and 2 at the left deltoid area 3 by experienced pediatric nurses. The antiHBs titers were measured at 1, 2, and 3 months after the first DDHBVV. The antiHBs 10 mIU/mL were considered protective. Good responders were defined as adolescents with antiHBs 100 mIU/mL. 5 All analyses were undertaken using STATA, version 10.0 (StataCorp, College Station, Texas).
Seven HIV-infected adolescents were enrolled from HIV-NAT, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand. In all, 6 (85.7%) were male, mean age was 15.4 years, CD4 count was 775 cells/mm 3 , and all had HIV-RNA <50 copies/ mL. Their characteristics at this second HBVV revaccination with DDHBVV are shown in Table 1 . All were infected with HIV via mother-to-child transmission. All completed 3 doses of HBVV during their infancy and were revaccinated after immune recovery with a course of 3-dose HBVV; 4 adolescents previously received intradermal HBVV (2 mg/dose) and 3 previously received intramuscular HBVV (10 mg/dose). 5 The mean duration from last dose of HBVV revaccination to the first dose of DDHBVV was 1.2 years.
Proportions of adolescents with protective antiHBs were 85.7% at months 1 and 2 and 100% at month 3. Geometric means of antiHBs were 1.1 mIU/mL at baseline, 101.6 mIU/mL at 1 month, 137.1 mIU/mL at 2 months, and 355.9 mIU/mL at 3 months after the first DDHBVV (Table 1) .
There was no grade 3 or 4 adverse events related to DDHBVV. No one reported fever or swelling at the injection site. In our study, the response rate to HBVV revaccination is better than the reports of revaccination of standard dose or DDHBVV in HIV-infected adults which were reported in a range of 51% to 85%. [2] [3] [4] This might be explained by the characteristics of our participants including young age group and high CD4 counts. 4 To our knowledge, our study is the first to report on DDHBVV in nonresponsive HIV-infected adolescents. However, the long-term immunogenicity after DDHBVV in these adolescents should be evaluated. Our study had limited number of HIV-infected adolescents. The randomized studies on DDHBVV versus standard HBVV in nonresponsive HIVinfected children and adolescents should be conducted.
In conclusion, DDHBVV at months 0, 1, and 2 is effective and safe. All 7 adolescents responded well after completing the 3 doses of DDHBVV. The DDHBVV is an option for HIV-infected adolescents who failed to respond to standard HBVV revaccination. 
